Audentes rises on additional myopathy data

Audentes Therapeutics Inc. (NASDAQ:BOLD) ended the week at $38.24, up $4.04 (12%), after an oral presentation of updated interim data from the first cohort of the dose-escalation Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM).

The Wednesday presentation at the American Society of Gene and Cell Therapy meeting in Chicago included additional follow-up from three patients and data from additional patients since the company first reported results in January (see BioCentury Extra, Jan. 4)...